Patents by Inventor Kathryn Taci-Jane Klose

Kathryn Taci-Jane Klose has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Transdermal delivery rate control using amorphous pharmaceutical compositions
    Patent number: 8357393
    Abstract: A pharmaceutical composition for transdermal delivery comprising one or more physiologically active agents; one or more dermal penetration enhancers; and a volatile pharmaceutically acceptable carrier comprising a volatile solvent; and wherein the physiologically active agent and dermal penetration enhancer form an amorphous deposit upon evaporation of the volatile carrier, said amorphous deposit forming a reservoir within the stratum corneum; and (A) wherein the composition has a release rate profile of physiologically active agent so as to provide a ratio of the maximum concentration (Cmax) to the average concentration (Cavg) for the physiologically active agent over the dosage interval within the range of 1 to 10.
    Type: Grant
    Filed: December 7, 2004
    Date of Patent: January 22, 2013
    Assignee: Acrux DDS Pty Ltd.
    Inventors: Timothy Matthias Morgan, Nina Frances Wilkins, Kathryn Taci-Jane Klose, Barrie Charles Finnin, Barry Leonard Reed
  • TRANSDERMAL DELIVERY RATE CONTROL USING AMORPHOUS PHARMACEUTICAL COMPOSITIONS
    Publication number: 20100166674
    Abstract: A pharmaceutical composition for transdermal delivery comprising one or more physiologically active agents; one or more dermal penetration enhancers; and a volatile pharmaceutically acceptable carrier comprising a volatile solvent; and wherein the physiologically active agent and dermal penetration enhancer form an amorphous deposit upon evaporation of the volatile carrier, said amorphous deposit forming a reservoir within the stratum corneum; and (A) wherein the composition has a release rate profile of physiologically active agent so as to provide a ratio of the maximum concentration (Cmax) to the average concentration (Cavg) for the physiologically active agent over the dosage interval within the range of 1 to 10.
    Type: Application
    Filed: December 18, 2009
    Publication date: July 1, 2010
    Inventors: Timothy Matthias Morgan, Nina Frances Wilkins, Kathryn Taci-Jane Klose, Barrie Charles Finnin, Barry Leonard Reed